利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

93 条记录 (耗时 0.016 秒)

    THERAPEUTICAL USES OF ESLICARBAZEPINE
    11.
    发明公开
    THERAPEUTICAL USES OF ESLICARBAZEPINE 无效
    治疗安息芬芬

    公开(公告)号：EP2121138A1

    公开(公告)日：2009-11-25

    申请号：EP08705172.8

    申请日：2008-01-14

    申请人： BIAL - Portela & Ca., S.A.

    发明人： SOARES DA SILVA, Patrício Manuel Vieira Araújo

    IPC分类号： A61P25/08 ,  A61P25/04 ,  A61P25/28 ,  A61P25/18 ,  A61K31/55 ,  A61K45/06

    CPC分类号： A61K31/55 ,  A61K45/06 ,  A61K2300/00

    摘要： New applications of eslicarbazepine and eslicarbazepine acetate in the treatment of intractable conditions, selected from epilepsy, central and peripheric nervous system disorders, affective disorders, schizoaffective disorders, bipolar disorders, attention disorders, anxiety disorders, neurophatic pain and neuropathic pain- related disorders, sensorimotor disorders, vestibular disorders, and nervous function alterations in degenerative and post-ischemic diseases. Preferably the intractable condition is, at least in part, caused by an overexpression of P-gp or MRP.

    摘要翻译： eslicarbazepine和eslicarbazepine acetate的新应用治疗难治性疾病，选自癫痫，中枢和周围神经系统疾病，情感障碍，分裂情感障碍，双相情感障碍，注意力障碍，焦虑症，神经性疼痛和神经性疼痛相关疾病，感觉运动 疾病，前庭障碍和退行性和缺血后疾病中的神经功能改变。 优选地，难治性病症至少部分地由P-gp或MRP的过度表达引起。

    DRUG COMBINATIONS
    14.
    发明公开
    DRUG COMBINATIONS 审中-公开
    药物的组合

    公开(公告)号：EP1983982A1

    公开(公告)日：2008-10-29

    申请号：EP07709265.8

    申请日：2007-01-15

    申请人： BIAL - Portela & Ca., S.A.

    发明人： LEARMONTH, David Alexander ,  BELIAEV, Alexander ,  SOARES DA SILVA, Patrício Manuel Vieira Araújo

    IPC分类号： A61K31/4164 ,  A61P43/00

    CPC分类号： A61K31/4164

    摘要： A combination comprising at least two components selected from: (i) compounds of formula I: R where R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R4 signifies hydrogen, alkyl or alkylaryl group; X signifies CH2, oxygen atom or sulphur atom; n is 1, 2 or 3, with the proviso that when n is 1, X is not CH2; and the individual (R)- and (S)-enantiomers or mixtures of enantiomers and pharmaceutically acceptable salts thereof; wherein the term alkyl means hydrocarbon chains, straight or branched, containing from one to six carbon atoms, optionally substituted by aryl, alkoxy, halogen, alkoxycarbonyl or hydroxy carbonyl groups; the term aryl means a phenyl or naphthyl group, optionally substituted by alkyloxy, halogen or nitro group; the term halogen means fluorine, chlorine, bromine or iodine; and (ii) at least one compound from the following classes of compounds: diuretics; beta-adrenergic antagonists; alpha2-adrenergic agonists; alphal -adrenergic antagonists; dual beta- and alpha-adrenergic antagonists; calcium channel blockers; potassium channel activators; anti-arrhythmics; ACE inhibitors; ATI receptor antagonists; renin inhibitors; lipid lowerers, vasopeptidase inhibitors; nitrates; endothelin antagonists; neutral endopeptidase inhibitors; anti-angiotensin vaccines; vasodilators; phosphodiesterase inhibitors; cardiac glycosides; serotonin antagonists; and CNS acting agents.